

# Medicines and Healthcare products Regulatory Agency

## MANUFACTURER'S AUTHORISATION

|   |   |
|---|---|
| <b>1: Authorisation Number</b>  | UK MIA 3473   |
| <b>2: Name of authorisation holder</b>  | NHS NATIONAL SERVICES SCOTLAND  |
| <b>3: Address(es) of manufacturing site(s)</b>  | NHS NATIONAL SERVICES SCOTLAND, THE JACK COPLAND CENTRE, 52 RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK, RICcartON, CURRIE, EH14 4BE, UNITED KINGDOM |
| <b>4: Legally registered address of authorisation holder</b>  | NHS NATIONAL SERVICES SCOTLAND, THE JACK COPLAND CENTRE, 52 RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK, RICcartON, CURRIE, EH14 4BE, UNITED KINGDOM |
| <b>5: Scope of authorisation and dosage forms</b>   | ANNEX 1 and/ or ANNEX 2   |
| <b>6: Legal Basis of authorisation</b>  | Regulation 17 of The Human Medicines Regulations 2012 (SI 2012/1916)  |
| <b>7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation</b> | Confidential  |
| <b>8: Authorisation Date</b>  | 21/09/2023  |
| <b>9: Annexes attached</b>  | Annex 1 and/or Annex 2  |

### SCOPE OF AUTHORISATION

#### Annex 1

Name and address of the site:

**NHS NATIONAL SERVICES SCOTLAND**, THE JACK COPLAND CENTRE, 52 RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK, RICcartON, CURRIE, EH14 4BE, UNITED KINGDOM

|   |
|---|
| Human Medicinal Products  |
| Authorised Operations   |
| MANUFACTURING OPERATIONS (according to part 1)  |
| <b>Part 1 - MANUFACTURING OPERATIONS</b><br><b>[ 1.1 ] Sterile Products</b><br>[ 1.1.3 ] Batch certification<br><b>[ 1.3 ] Biological medicinal products</b><br>[ 1.3.1 ] Biological medicinal products<br>[ 1.3.1.2 ] Immunological products<br>[ 1.3.1.3 ] Cell therapy products<br>[ 1.3.1.8 ] Other biological medicinal products<br>ATMPs as stipulated in 1394/2007 |

[ 1.3.2 ] Batch certification

[ 1.3.2.2 ] Immunological products

**[ 1.4 ] Other products or manufacturing activity**

[ 1.4.1 ] Manufacture of:

[ 1.4.1.4 ] Products authorised under regulation 174 (supply in response to spread of pathogenic agents etc)

**[ 1.5 ] Packaging**

[ 1.5.2 ] Secondary packaging